WuXi Biologics (Cayman) Inc
HKEX:2269
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
WuXi Biologics (Cayman) Inc (2269) under the Base Case is HKD per share.
Compared with the current market price of 46.56 HKD, the stock appears .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
What one share is worth in the bear, base and bull cases.
Create a free account · No card needed
Do our valuations actually work? See backtest results .
Intrinsic value next to the price over the past 5 years, and what happened after valuations like today’s.
Create a free account · No card needed
Fundamental Analysis
What WuXi Biologics (Cayman) Does
WuXi Biologics is a contract development and manufacturing company for biologic drugs, such as antibodies and other protein-based medicines. It helps drug makers move a biologic from early research through process development, testing, and commercial manufacturing, rather than making medicines for its own brand. Its customers are mainly pharmaceutical and biotech companies that need outside expertise, lab capacity, and production scale.
- Headquarters
- China CN
- Employees
- 13 252
- IPO date
- Jun 13, 2017
WuXi Biologics (Cayman) has a narrow economic moat
Moving an established drug-production process away from WuXi Biologics can take substantial time and money, making customers reluctant to switch simply for a lower price. Some customers also owe technology royalties when using another manufacturer, giving WuXi protection beyond the manufacturing work itself.
Read the full moat analysis
Earnings Waterfall
WuXi Biologics (Cayman) Inc
What is the Intrinsic Value of one WuXi Biologics (Cayman) Inc stock?
The intrinsic value for WuXi Biologics (Cayman) Inc (2269) under the Base Case is HKD.
Is WuXi Biologics (Cayman) Inc stock undervalued or overvalued?
Compared with the current market price of 46.56 HKD, the stock appears .
